Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects

Joerg Herrmann(Mayo Clinic), Joshua D. Mitchell(Washington University in St. Louis), Elena Deych, Anju Nohria(Brigham and Women's Hospital), Ana Barac(National Institute of Dental and Craniofacial Research), Jennifer Liu(Memorial Sloan Kettering Cancer Center), Andrés J. Daniele(Universidad de Buenos Aires), Ariane Vieira Scarlatelli Macedo(Santa Casa Hospital), Daniel J. Lenihan(Saint Francis Medical Center), Susan Dent(Government of the United States of America), Aaron L. Sverdlov(Hunter New England Local Health District), Giselle Alexandra Suero‐Abreu(Massachusetts General Hospital), Michael G. Fradley(University of South Florida), Joseph R. Carver(American Society of Clinical Oncology), Charles Porter(University of Kansas Medical Center), Tienush Rassaf(West German Heart and Vascular Center Essen), Darryl P. Leong(Hamilton Health Sciences), Dae Hyun Lee(University of South Florida), Meghan J. Mooradian(Massachusetts General Hospital), Tomas G. Neilan(Duke Medical Center), Paaladinesh Thavendiranathan(Toronto General Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Alexander R Lyon(Royal Brompton Hospital), Richard K. Cheng(University of Washington Medical Center)
JAMA Oncology
November 13, 2025
Cited by 10


Related Papers